U.S. flag An official website of the United States government
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. China Daheng Group Inc. - 07/18/2014
  1. Warning Letters


China Daheng Group Inc.

China Daheng Group Inc.

United States

Issuing Office:

United States


Department of Health and Human Services logoDepartment of Health and Human Services

Public Health Service
Food and Drug Administration
 10903 New Hampshire Avenue
Silver Spring, MD 20993 

JUL 18, 2014

Ms. Xiaohong Yang, General Manager
China DaHeng Group, Inc.
#A9 Shangdi Xinxilu, Haidian District
Beijing, 100085, China

Dear Ms. Yang:

The Food and Drug Administration has completed an evaluation of your firm's corrective actions in response to our Warning Letter CMS # 411469, dated January 15, 2014. Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not rel ieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Carl Fischer, Ph.D.
Acting Director
Division of International
Compliance Operations
Office of Compliance
Center for Devices and
Radiologic Health

Back to Top